文献速递银屑病与炎症性皮肤病

毛发红糠疹的管理与遗传背景:单中心经验

The management and genetic background of pityriasis rubra pilaris: a single-centre experience.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-03-03

该回顾性研究纳入2006至2016年间在该院诊断的19例毛发红糠疹(PRP)患者,评估所用疗法疗效并筛查CARD14基因变异。多数患者经阿维A联合系统性糖皮质激素治疗成功,19例中10例携带不同CARD14基因变异,但未发现治疗反应与遗传背景之间的相关性。

要点

  • 19例PRP患者中17例为I型、1例III型、1例V型
  • 多数患者经阿维A联合系统性糖皮质激素治疗成功
  • 19例中10例携带CARD14基因变异,与治疗反应无相关性

核心结论

  • 基于该院经验,作者提出阿维A联合初始短期系统性糖皮质激素治疗可能是PRP的成功治疗选择。
  • 尽管近半数病例检出多种CARD14变异,但未发现治疗反应与遗传背景之间的相关性。
  • 该数据支持既往观察,即CARD14基因变异对PRP不具特异性,尽管它们可能提示慢性炎症。

研究设计与样本

  • 回顾性研究,纳入2006至2016年间在该院诊断的PRP患者,共分析19例。
  • 除治疗随访外,对CARD14基因进行遗传学分析。

主要发现

  • 19例患者中17例诊断为I型PRP,1例为III型,1例为V型。
  • 多数患者经阿维A联合系统性糖皮质激素治疗成功,其余患者接受其他系统性治疗,效果不一。
  • CARD14基因筛查发现两个既往已描述的突变(rs114688446、rs117918077)和六个多态性(rs28674001、rs2066964、rs34367357、rs11653893、rs11652075、rs2289541)。
  • 19例中10例单独或组合携带不同的CARD14基因变异。

临床怎么用

  • 作者提出阿维A联合初始短期系统性糖皮质激素治疗可能是PRP的成功治疗选择。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory dermatosis with multifactorial aetiology. It is known that particular caspase recruitment domain family member 14 (CARD14) gene mutations are associated with familial PRP and certain forms of psoriasis. Additionally, few data are available about the role of CARD14 gene variants in sporadic PRP. The clinical picture is variable for the different types of PRP, therefore choosing the adequate treatment is often difficult, furthermore there are no specific guidelines for therapy. OBJECTIVE: Our aim was to survey the efficacy of the applied therapies and to screen the CARD14 gene variants in our PRP patients. METHODS: In this retrospective study, patients diagnosed with PRP between 2006 and 2016 at our clinic were involved. Besides the follow-up study of the treatments, the genetic analysis of CARD14 gene was performed. RESULTS: We analysed 19 patients, among whom 17 were diagnosed with type I, one with type III, and one with type V PRP. The majority of the patients were successfully treated with acitretin in combination with systemic corticosteroids, and the remaining patients were treated with other systemic therapies with diverse effects. The genetic screening of CARD14 gene revealed two previously described mutations (rs114688446, rs117918077) and six polymorphisms (rs28674001, rs2066964, rs34367357, rs11653893, rs11652075, rs2289541). Ten of 19 patients carried different CARD14 genetic variants either alone or in combination. CONCLUSION: Based on our experience, we propose that acitretin and an initial combination of short-term systemic corticosteroid therapy could be a successful treatment option for PRP. Although we identified several CARD14 variants in almost half of our cases, we did not find a correlation between the therapeutic response and the genetic background. Our data support the previous observation that CARD14 genetic variants are not specific to PRP, although they may indicate chronic inflammation.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gál B, Göblös A, Danis J, et al. The management and genetic background of pityriasis rubra pilaris: a single-centre experience. J Eur Acad Dermatol Venereol. 2019. PMID: 30697821. doi:10.1111/jdv.15455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。